EUROPEAN SURVEILLANCE NETWORK TO MONITOR THE LONG TERM EFFECTIVENESS AND SAFETY OF SYSTEMIC AGENTS IN THE TREATMENT OF PSORIASIS
What is Psonet
Psonet is a network of independent European, population-based, registries of patients suffering from psoriasis or psoriatic arthritis, being treated by systemic agents. These include, according to the registry, both conventional and biological agents or are restricted to biological agents. Patients entered in the registries are followed up over time. Through such a collaboration, coordinated post-marketing surveillance studies can be developed, that would not be feasible in a single country. The following analyses are of particular interest:
- Investigation of the clinical effectiveness of systemic treatments for psoriasis, in a population context;
- Identification of prognostic factors that can help in predicting the response to systemic treatments;
- Monitoring of adverse effects of systemic treatments, with particular attention to long-term and rare adverse events, such as severe infections and cancers.
Once the network has been well established, it may be extended, with relative ease, to the monitoring of new therapeutic agents introduced in the future, and serve as a model for pharmacoepidemiology and independent post marketing surveillance in Europe.